The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.